Trial Profile
A Multicenter Phase IB Dose Escalation Study to Evaluate the Safety, Feasibility and Efficacy of the Torisel-Rituximab-Cyclophosphamide-Doxorubicin-Vincristine-Prednisone (T-R-CHOP), Torisel-Rituximab-Fludarabine-Cyclophosphamide (T-R-FC) and Torisel-Rituximab-Aracytine High Dose-Dexamethasone (T-R-DHA) for the Treatment of Patients in Relapsed/Refractory Mantle Cell Lymphoma.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 28 Jul 2020
Price :
$35
*
At a glance
- Drugs Temsirolimus (Primary) ; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Fludarabine; Prednisone; Rituximab; Vincristine
- Indications Mantle-cell lymphoma
- Focus Adverse reactions
- Acronyms T3
- 01 Aug 2020 Results published in the Annals of Hematology
- 08 Mar 2017 Status changed from active, no longer recruiting to completed.
- 16 Oct 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.